Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Guselkumab effectively reduces fatigue in Psoriatic Arthritis patients over two years.

This study found that Golvatinib, Gliquidone, and Dihydroergotamine may inhibit the binding of SARS-CoV-2's Nsp1 protein to the host ribosomal subunit, suggesting potential as treatments against COVID-19 variants.

This study identified a series of novel β-glucuronidase inhibitors that may help mitigate adverse effects of first-line anti-cancer drugs by targeting gut bacteria, based on virtual high-throughput screening findings.

This study identified several gonadal hormone drugs, including toremifene citrate, tamoxifen citrate, and clomiphene citrate, that effectively inhibited filovirus entry in a pseudovirus model.

This study reports that a novel series of compounds can potently and selectively inhibit glycogen synthase kinase-3, which activates glycogen synthase in insulin receptor-expressing cells and primary rat hepatocytes.

This study reports that hedgehog pathway inhibitors, sonidegib and vismodegib, showed distinct adverse event patterns in real-world data, suggesting the need for further research to confirm these findings.

In this study, a UK expert panel discussed strategies for managing common side effects of vismodegib, a hedgehog pathway inhibitor used for advanced basal cell carcinoma, concluding that adverse events like taste disturbances and muscle cramps can be effectively managed to optimize treatment duration.

This review reports that sonidegib and vismodegib, two Hedgehog inhibitors used for treating advanced basal cell carcinoma, have similar efficacy and safety profiles, but differ in pharmacokinetics, with sonidegib achieving peak concentration more rapidly and reaching steady state later than vismodegib.

This study found that topical patidegib gel significantly shrank basal cell carcinomas in Gorlin syndrome patients without causing the systemic side effects common with oral hedgehog inhibitors.

This study identified several compounds, including Pictilisib and Nimorazole, that may have higher binding affinity for SARS-CoV-2 main protease than existing inhibitors, potentially offering new treatment alternatives for Covid-19.

This review explores enzyme inhibitors from gorgonians and soft corals and highlights their potential industrial and biomedical applications, but it reports no new experimental results.

This review highlights that while sonidegib and vismodegib offer promising treatment options for advanced basal cell carcinoma, their use is often limited by treatment-emergent adverse events, which can be managed through protocol modifications and supportive interventions.

This study found that Cyanidin-3-O-glucoside and Vitisin A were able to penetrate mouse skin and improve issues related to hair follicle miniaturization and apoptosis in androgenetic alopecia, suggesting these compounds as potential alternative treatments for hair loss.

This study identified natural compounds from Iris plants that showed potential as inhibitors of urease and carbonic anhydrase-II enzymes, suggesting their possible use in treating related disorders.

The study reported that vismodegib showed significant effectiveness in treating basal cell carcinoma, particularly in patients with Gorlin-Goltz syndrome or locally advanced BCC, but also highlighted substantial side effects, requiring careful management to prevent treatment resistance and maintain remission.

This study found that vismodegib was effective in treating basal cell carcinoma, achieving complete remission in some patients; however, significant side effects often required careful management to prevent therapy suspension, which can lead to resistance.

This case report details an occurrence of Vogt-Koyanagi-Harada disease during pegylated interferon-α2b and ribavirin therapy for chronic hepatitis C.

This study found that inhibiting the PI3Kδ enzyme in murine models of cutaneous chronic graft-versus-host disease (cGVHD) reduced skin scores and fibrosis, prevented pathogenic lymphoid structures, and improved survival, suggesting it as a promising therapeutic approach to address the disease's hypoxic pathophysiology.

Combining MMP-9 and JAK inhibitors can effectively prevent skin depigmentation in vitiligo.

This study suggests that natural molecules like curcumin, EGCG, barringtozenol, and finasteride may be effective inhibitors for VEGFR, potentially offering a cancer chemoprevention alternative to pazopanib.

This study identified known and potential novel adverse events, such as squamous cell carcinoma and dehydration, for vismodegib, underlining the importance of monitoring especially in the first two months of treatment.

This study found that WISP-1 plays a key role in ligamentum flavum fibrosis through the Hedgehog-Gli1 pathway, with cyclopamine showing potential to reduce fibrosis effects in a rabbit model.

This study discusses the role of CD8+ T-cell and interferon γ signaling in vitiligo's pathogenesis and notes that JAK inhibitors, which are FDA-approved for other autoimmune diseases, may offer a potential treatment path by blocking this pathway.

This study suggests that combining baricitinib with narrowband UV-B therapy is an effective and well-tolerated approach for treating active nonsegmental vitiligo.

Isoginkgetin reduces inflammation in cells by blocking NF-κB activation.

This study found that simvastatin interfered with insulin-induced VEGF expression and keratinocyte proliferation during skin repair in mice, effects that could be reversed by mevalonate.

This study found that the purified compound VB1 from Vitex negundo seeds may reduce UVA-induced skin aging by targeting MAPK1 and demonstrated its potential in mice.

This study investigated pyranoanthocyanin Vitisin A and found it significantly lowered triglyceride levels and reduced body weight in high-fat diet-fed mice, outperforming Cyanidin-3-O-glucoside by inhibiting hepatic lipogenesis and enhancing fatty acid β-oxidation.

This letter discusses potential hair loss effects of Hedgehog inhibitors but presents no new clinical findings, urging further exploration of this possible class effect.